Selected article for: "activate factor and lung inflammation"
Author: Montero, Paula; Milara, Javier; Roger, Inés; Cortijo, Julio
Title: Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms
  • Cord-id: g0w1tdux
  • Document date: 2021_6_9
    • ID: g0w1tdux
    Snippet: Interstitial lung diseases (ILDs) comprise different fibrotic lung disorders characterized by cellular proliferation, interstitial inflammation, and fibrosis. The JAK/STAT molecular pathway is activated under the interaction of a broad number of profibrotic/pro-inflammatory cytokines, such as IL-6, IL-11, and IL-13, among others, which are increased in different ILDs. Similarly, several growth factors over-expressed in ILDs, such as platelet-derived growth factor (PDGF), transforming growth fact
    Document: Interstitial lung diseases (ILDs) comprise different fibrotic lung disorders characterized by cellular proliferation, interstitial inflammation, and fibrosis. The JAK/STAT molecular pathway is activated under the interaction of a broad number of profibrotic/pro-inflammatory cytokines, such as IL-6, IL-11, and IL-13, among others, which are increased in different ILDs. Similarly, several growth factors over-expressed in ILDs, such as platelet-derived growth factor (PDGF), transforming growth factor β1 (TGF-β1), and fibroblast growth factor (FGF) activate JAK/STAT by canonical or non-canonical pathways, which indicates a predominant role of JAK/STAT in ILDs. Between the different JAK/STAT isoforms, it appears that JAK2/STAT3 are predominant, initiating cellular changes observed in ILDs. This review analyzes the expression and distribution of different JAK/STAT isoforms in ILDs lung tissue and different cell types related to ILDs, such as lung fibroblasts and alveolar epithelial type II cells and analyzes JAK/STAT activation. The effect of JAK/STAT phosphorylation on cellular fibrotic processes, such as proliferation, senescence, autophagy, endoplasmic reticulum stress, or epithelial/fibroblast to mesenchymal transition will be described. The small molecules directed to inhibit JAK/STAT activation were assayed in vitro and in in vivo models of pulmonary fibrosis, and different JAK inhibitors are currently approved for myeloproliferative disorders. Recent evidence indicates that JAK inhibitors or monoclonal antibodies directed to block IL-6 are used as compassionate use to attenuate the excessive inflammation and lung fibrosis related to SARS-CoV-2 virus. These altogether indicate that JAK/STAT pathway is an attractive target to be proven in future clinical trials of lung fibrotic disorders.

    Search related documents:
    Co phrase search for related documents
    • acute phase and adaptive immune response activation: 1
    • acute phase and lung biopsy: 1, 2, 3, 4
    • acute phase and lung blood: 1, 2, 3, 4, 5, 6
    • acute phase and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute phase and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • acute phase and lung fibroblast: 1
    • acute phase and lung increase: 1, 2, 3, 4, 5
    • acute phase and lung infect: 1
    • acute phase and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
    • acute phase and lung interstitium: 1, 2
    • acute phase and lung parenchyma: 1, 2, 3, 4
    • acute phase and lung sample: 1
    • acute phase and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute phase and lung tissue increase: 1
    • acute phase and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • adaptive immune response and lung architecture: 1
    • adaptive immune response and lung blood: 1
    • adaptive immune response and lung damage: 1, 2, 3, 4, 5, 6
    • adaptive immune response and lung disease: 1, 2, 3, 4, 5, 6